Bean Leaf Extract Inhibits Atrogin1 and Murf1 to Prevent Muscle Loss

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preventing muscle loss, particularly in the elderly, are inadequate, with branched-chain amino acids showing little effect, and existing solutions have significant side effects or are not economically viable.

Innovation Solution

A composition using bean leaf extract as an active ingredient, specifically from stages R6 to R8 of the bean plant's growth, which inhibits the expression of ubiquitin ligases Atrogin1 and Murf1, thereby preventing muscle loss and associated myopathies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If branched-chain amino acids (BCAA) are used to prevent muscle loss, then muscle preservation is attempted, but the effect is negligible and does not fundamentally solve sarcopenia

Engineering Contradiction:

Improveeffectiveness in preventing muscle lossVSAvoidimpact on skeletal muscle mass changes

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent shifts the target parameter from amino acid supplementation (BCAA) to plant extract supplementation (bean leaf extract), changing the fundamental substance parameter to achieve effective inhibition of muscle loss through different biochemical mechanisms

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The bean leaf extract acts as an intermediary substance that inhibits the expression of ubiquitin ligases (Atrogin1 and Murf1), thereby preventing muscle protein degradation without directly supplementing muscle building blocks

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If existing pharmaceutical solutions are used to inhibit muscle loss, then muscle preservation may be achieved, but side effects increase and economic viability decreases

Engineering Contradiction:

Improvemuscle loss inhibitionVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs bean leaf extract, a natural plant substance that is inexpensive, easily obtainable, and free from the severe side effects of synthetic pharmaceuticals, providing an economically viable and safe alternative for muscle loss prevention

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent converts the potentially harmful effect of ubiquitin ligase overexpression (which causes muscle degradation) into a beneficial target by using bean leaf extract to specifically inhibit these ligases, thereby transforming the disease mechanism into a therapeutic opportunity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS10898535B2Composition for inhibiting and preventing myopathy, containing bean leaf extract as active ingredient

Publication Date: 2021.01.26 AMOREPACIFIC CORP

AI summary

The present invention relates to a composition for inhibiting and preventing myopathy comprising a bean leaf extract as an active ingredient. More specifically, the composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.